Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding

Journal of Virology

Volumn 84, Issue 2, 2010, Pages 1139-1147

  Busse, Clemens ^a   Feederle, Regina ^a   Schnölzer, Martina ^a   Behrends, Uta ^b   Mautner, Josef ^b   Delecluse, Henri Jacques ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIGEN; CD19 ANTIBODY; CD21 ANTIBODY; CD22 ANTIBODY; CELL ANTIBODY; GLYCOPROTEIN; GLYCOPROTEIN GP350; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; ENDOSOME; EPSTEIN BARR VIRUS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFECTION RATE; INTERNALIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; RAJI CELL; T LYMPHOCYTE ACTIVATION; VIRUS CAPSID;

ANTIBODIES; ANTIGENS, CD19; ANTIGENS, CD22; B-LYMPHOCYTES; CELL LINE; ENDOSOMES; HERPESVIRUS 4, HUMAN; HUMANS; RECEPTORS, COMPLEMENT 3D; TRANSFECTION; VIRAL MATRIX PROTEINS; VIRION;

HUMAN HERPESVIRUS 4; MIRIDAE;

EID: 73849116090     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01953-09     Document Type: Article

References (55)

1. + T-cell preparations for therapy. PLoS ONE 2:e583.
2. Adhikary, D., U. Behrends, A. Moosmann, K. Witter, G. W. Bornkamm, and J. Mautner. 2006. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J. Exp. Med. 203:995-1006.
3. Anderson, D. B., S. Laquerre, K. Ghosh, H. P. Ghosh, W. F. Goins, J. B. Cohen, and J. C. Glorioso. 2000. Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry. J. Virol. 74:2481-2487.
4. Arndt, M. A., J. Krauss, R. Schwarzenbacher, B. K. Vu, S. Greene, and S. M. Rybak. 2003. Generation of a highly stable, internalizing anti-CD22 singlechain Fv fragment for targeting non-Hodgkin's lymphoma. Int. J. Cancer 107:822-829.
5. Carroll, W. L., E. Mendel, and S. Levy. 1988. Hybridoma fusion cell lines contain an aberrant kappa transcript. Mol. Immunol. 25:991-995.
6. D'Addario, M., T. A. Libermann, J. Xu, A. Ahmad, and J. Menezes. 2001. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human Blymphocytes via CD21, involving activation of NF-κB and different signaling pathways. J. Mol. Biol. 308:501-514.
7. Datsenko, K. A., and B. L. Wanner. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. USA 97:6640-6645.
8. Delecluse, H. J., T. Hilsendegen, D. Pich, R. Zeidler, and W. Hammerschmidt. 1998. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl. Acad. Sci. USA 95:8245-8250.
9. Feederle, R., H. Bannert, H. Lips, N. Muller-Lantzsch, and H. J. Delecluse. 2009. The Epstein-Barr virus alkaline exonuclease BGLF5 serves pleiotropic functions in virus replication. J. Virol. 83:4952-4962.
10. Fingeroth, J. D., J. J. Weis, T. F. Tedder, J. L. Strominger, P. A. Biro, and D. T. Fearon. 1984. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc. Natl. Acad. Sci. USA 81:4510-4514.
11. Gong, M., and E. Kieff. 1990. Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110. J. Virol. 64:1507-1516.
12. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74.
13. Haddad, R. S., and L. M. Hutt-Fletcher. 1989. Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells. J. Virol. 63:4998-5005.
14. Hayflick, L. 1965. The limited in vitro lifetime of human diploid cell strains. Exp. Cell Res. 37:614-636.
15. Hoffman, G. J., S. G. Lazarowitz, and S. D. Hayward. 1980. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc. Natl. Acad. Sci. USA 77:2979-2983.
16. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, and L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61-68.
17. Hummel, M., D. Thorley-Lawson, and E. Kieff. 1984. An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200). J. Virol. 49:413-417.
18. Hutt-Fletcher, L. M. 2007. Epstein-Barr virus entry. J. Virol. 81:7825-7832.
19. Janz, A., M. Oezel, C. Kurzeder, J. Mautner, D. Pich, M. Kost, W. Hammerschmidt, and H. J. Delecluse. 2000. Infectious Epstein-Barr virus lacking major glycoprotein BLLF1 (gp350/220) demonstrates the existence of additional viral ligands. J. Virol. 74:10142-10152.
20. Kamiyama, H., G. Zhou, and B. Roizman. 2005. Herpes simplex virus 1 recombinant virions exhibiting the amino-terminal fragment of urokinasetype plasminogen activator can enter cells via the cognate receptor. Gene Ther. 13:621-629.
21. Kipriyanov, S. M., G. Moldenhauer, G. Strauss, and M. Little. 1998. Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77:763-772.
22. Li, Q. X., L. S. Young, G. Niedobitek, C. W. Dawson, M. Birkenbach, F. Wang, and A. B. Rickinson. 1992. Epstein-Barr virus infection and replication in a human epithelial cell system. Nature 356:347-350.
23. Lowell, C. A., L. B. Klickstein, R. H. Carter, J. A. Mitchell, D. T. Fearon, and J. M. Ahearn. 1989. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J. Exp. Med. 170:1931-1946.
24. Menotti, L., A. Cerretani, H. Hengel, and G. Campadelli-Fiume. 2008. Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J. Virol. 82:10153-10161.
25. Menotti, L., G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P. L. Lollini, and G. Campadelli-Fiume. 2009. Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc. Natl. Acad. Sci. USA 106:9039-9044.
26. Molesworth, S. J., C. M. Lake, C. M. Borza, S. M. Turk, and L. M. Hutt-Fletcher. 2000. Epstein-Barr virus gH is essential for penetration of B cells but also plays a role in attachment of virus to epithelial cells. J. Virol. 74:6324-6332.
27. Moosmann, A., N. Khan, M. Cobbold, C. Zentz, H. J. Delecluse, G. Hollweck, A. D. Hislop, N. W. Blake, D. Croom-Carter, B. Wollenberg, P. A. Moss, R. Zeidler, A. B. Rickinson, and W. Hammerschmidt. 2002. B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells. Blood 100:1755-1764.
28. Morgan, C., H. M. Rose, and B. Mednis. 1968. Electron microscopy of herpes simplex virus. I. Entry. J. Virol. 2:507-516.
29. Nemerow, G. R., and N. R. Cooper. 1984. Early events in the infection of human B lymphocytes by Epstein-Barr virus: the internalization process. Virology 132:186-198.
30. Nemerow, G. R., R. A. Houghten, M. D. Moore, and N. R. Cooper. 1989. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell 56:369-377.
31. Nemerow, G. R., C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420.
32. Nemerow, G. R., J. J. Mullen III, P. W. Dickson, and N. R. Cooper. 1990. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection. J. Virol. 64:1348-1352.
33. Neuhierl, B., and H. J. Delecluse. 2005. Molecular genetics of DNA viruses: recombinant virus technology. Methods Mol. Biol. 292:353-370.
34. Neuhierl, B., R. Feederle, D. Adhikary, B. Hub, K. Geletneky, J. Mautner, and H.-J. Delecluse. 2009. Primary B-cell infection with a ΔBALF4 Epstein-Barr virus comes to a halt in the endosomal compartment yet still elicits a potent CD4-positive cytotoxic T-cell response. J. Virol. 83:4616-4623.
35. Orlandi, R., D. H. Gussow, P. T. Jones, and G. Winter. 1989. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86:3833-3837.
36. Pulvertaft, R. J. V. 1964. Cytology of Burkitt's tumour (African lymphoma). Lancet 283:238-240.
37. Rooney, C. M., D. T. Rowe, T. Ragot, and P. J. Farrell. 1989. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J. Virol. 63:3109-3116.
38. Serafini-Cessi, F., N. Malagolini, M. Nanni, F. Dall'Olio, G. Campadelli-Fiume, J. Tanner, and E. Kieff. 1989. Characterization of N- and O-linked oligosaccharides of glycoprotein 350 from Epstein-Barr virus. Virology 170: 1-10.
39. Shan, D., and O. W. Press. 1995. Constitutive endocytosis and degradation of CD22 by human B cells. J. Immunol. 154:4466-4475.
40. Shannon-Lowe, C., G. Baldwin, R. Feederle, A. Bell, A. Rickinson, and H. J. Delecluse. 2005. Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth. J. Gen. Virol. 86:3009-3019.
41. Sinclair, A. J., and P. J. Farrell. 1995. Host cell requirements for efficient infection of quiescent primary B lymphocytes by Epstein-Barr virus. J. Virol. 69:5461-5468.
42. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13:3321-3328.
43. Spear, P. G., and R. Longnecker. 2003. Herpesvirus entry: an update. J. Virol. 77:10179-10185.
44. Strnad, B. C., M. R. Adams, and H. Rabin. 1983. Glycosylation pathways of two major Epstein-Barr virus membrane antigens. Virology 127:168-176.
45. Sugano, N., W. Chen, M. L. Roberts, and N. R. Cooper. 1997. Epstein-Barr virus binding to CD21 activates the initial viral promoter via NF-κB induction. J. Exp. Med. 186:731-737.
46. Szakonyi, G., M. G. Klein, J. P. Hannan, K. A. Young, R. Z. Ma, R. Asokan, V. M. Holers, and X. S. Chen. 2006. Structure of the Epstein-Barr virus major envelope glycoprotein. Nat. Struct. Mol. Biol. 13:996-1001.
47. Tanner, J., J. Weis, D. Fearon, Y. Whang, and E. Kieff. 1987. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 50:203-213.
48. Tanner, J., Y. Whang, J. Sample, A. Sears, and E. Kieff. 1988. Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. J. Virol. 62:4452-4464.
49. Tedder, T. F., L. T. Clement, and M. D. Cooper. 1984. Expression of C3d receptors during human B-cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J. Immunol. 133:678-683.
50. Turk, S. M., R. Jiang, L. S. Chesnokova, and L. M. Hutt-Fletcher. 2006. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J. Virol. 80:9628-9633.
51. Vidarsson, G., J. G. van de Winkel, and M. A. van Dijk. 2001. Multiplex screening for functionally rearranged immunoglobulin variable regions reveals expression of hybridoma-specific aberrant V-genes. J. Immunol. Methods 249:245-252.
52. Wang, X., and L. M. Hutt-Fletcher. 1998. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J. Virol. 72:158-163.
53. Wang, Z., M. Raifu, M. Howard, L. Smith, D. Hansen, R. Goldsby, and D. Ratner. 2000. Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3′ to 5′ exonuclease activity. J. Immunol. Methods 233:167-177.
54. Young, K. A., A. P. Herbert, P. N. Barlow, V. M. Holers, and J. P. Hannan. 2008. Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350. J. Virol. 82:11217-11227.
55. Zhou, G., and B. Roizman. 2005. Characterization of a recombinant herpes simplex virus 1 designed to enter cells via the IL13Rα2 receptor of malignant glioma cells. J. Virol. 79:5272-5277.